The novel role of HMGA2 in enhancing PARP1 PARylation activity and reducing efficacy of olaparib in blocking PARP1 function and PARP1 DNA trapping is expected to impact on tumor cell viability. This evidence concerns the gene PARP1 and neoplasm.